Celebrating 50 Years of Innovation

For the past five decades, Lerner David has thrived as an intellectual property boutique dealing with all aspects of IP. IP is not just our specialty; it is our passion and purpose. We assist a diverse client base at the forefront of the Fourth Industrial Revolution (4IR), protecting groundbreaking technologies from AI to 3D printing; renewable energy to autonomous vehicles; FinTech to telecommunications; pharmaceuticals to life-saving medical therapies. We safeguard some of the world’s leading brands. And we fight for our clients’ rights before the courts and administrative tribunals of the world.

As the world enters 4IR and we embark on our next 50 years, Lerner David stands at the ready to help innovators protect and bring tomorrow’s emerging technologies to life today.

Helping Clients Succeed

Lerner David Defeats Motion for Summary Judgement in Trademark Case

On December 20, 2018, Judge Wolfson in the United States District Court, District of New Jersey, denied Plaintiff’s summary judgment motion on all grounds that Defendant Reflections Center for Skin and Body, PC’s REFLECTIONS trademark is invalid. Plaintiff is a cosmetic surgery practice located in Freehold, NJ and operates under the name New Reflections Plastic Surgery LLC and was founded in August 2007. Defendant is a cosmetic medicine practice, with multiple locations in New Jersey, and was founded in 2000. In November 2001 Defendant obtained a New Jersey trademark registration for the ma...

In a Final Written Decision issued in favor of Lerner David clients Kashiv Pharma, LLC and Amneal Pharmaceuticals, LLC, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,034,376 invalid on both asserted grounds. The '376 Patent is directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Kashiv's ANDA directed to its own abuse-deterrent formulation of oxycodone. This marks the fourth IPR win for Kashiv against this family of patents. Collectively, ...

Global Trademark Skills Recognized

A global outlook characterises the thriving practice at Lerner David. This New Jersey boutique has its sights firmly trained on Asia; offices in China and Japan have brought in waves of new work, with many businesses looking for truly international trademark strategies. After determining which jurisdictions are most important to their clients, the team’s canny practitioners employ first-hand experience of the integrity of different trademark offices and courts around the world and then come up with a sound way forward. Of late, they have been particularly busy wrestling domain names away from ...

In a Final Written Decision issued in favor of Lerner David clients Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,034,376 invalid. The '376 Patent is directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Kashiv's ANDA directed to its own abuse-deterrent formulation of oxycodone. The case is Amneal Pharmaceuticals, LLC v. Purdue Pharma, L.P. et al., Case No. IPR2016-01413, (Jan. 17, 2018).